BPC-157 is a stable gastric pentadecapeptide studied for cytoprotection and tissue repair.

What the BPC-157 record actually contains

BPC-157 is a synthetic 15-amino-acid peptide — a pentadecapeptide — derived from a partial sequence of a protein found in human gastric juice ^[1]. Its authors call it a stable gastric pentadecapeptide because the fragment is reported to be stable in gastric juice. Across three decades of preclinical work it has been studied as a cytoprotective and regenerative compound, and the present console reads that record straight: what each study measured, in which species, by which route, with every quantitative claim wired to a citation.

The shape of the evidence is the first fact, not a footnote. The repair and protection findings are overwhelmingly preclinical — rats, a few dog pharmacokinetic measurements, and cell-culture work. Human data is thin: as of 2025 reviews, only three small human pilot studies exist ^[9][10][11]. There is no validated human dose, no large controlled efficacy trial, and no long-term human safety dataset. BPC-157 is not an FDA-approved drug, and in 2023 the FDA placed it in a category of bulk substances it identified as raising significant safety risks for compounding ^[13].

That is the honest frame, and the design encodes it literally: established cited findings sit on the near plane, the minimal human-pilot signal recedes a plane back, and the human-safety void sits at the dim far edge. Nothing here is dispensed, sold, or recommended for use. The pages below summarize the literature; the BPC-157 legal status and 503A category page handles the regulatory picture in full.

BPC-157 as a research peptide

BPC-157 (also written BPC 157, and developed industrially under designations PL 14736, PLD-116 and PL-10) is a synthetic peptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, molecular formula C62H98N16O22, and a molecular weight near 1419 Da (CAS 137525-51-0) ^[1]. It is frequently supplied as the acetate salt. It is not a hormone and not a growth factor; it is a short peptide studied in a research context.

The term research peptide is precise here. BPC-157 has no approved therapeutic indication anywhere, and outside formal studies it circulates through non-regulated channels where identity, purity and content are unverified ^[12]. This site treats it strictly as a subject of published research — the constituent of an evidence base, not a product. The single best-characterized mechanism is angiogenesis driven through the VEGFR2 receptor ^[3], detailed on the BPC-157 mechanism of action page.

What the research describes (reported effects)

Across animal models, the reported BPC-157 benefits cluster around two themes: accelerated soft-tissue repair and broad cytoprotection. In a fully transected rat Achilles tendon, BPC 157 (dosed at 10 µg, 10 ng or 10 pg per rat, once daily) improved biomechanical, functional, microscopic and macroscopic recovery versus untreated controls and stimulated tendocyte outgrowth in culture ^[2]. In a rat gastric-ulcer model it reduced ulcer area, with an ulcer-formation inhibition ratio of roughly 45.7-65.6% at the higher 800 ng/kg dose ^[4].

The cytoprotection lineage extends well beyond the gut — to liver, kidney, cardiac, ocular and ischemia-reperfusion models — and is the subject of the dedicated BPC-157 cytoprotection research page. These are animal findings. They describe what was measured in models, not benefits demonstrated in people. Claims that BPC-157 builds muscle, drives weight loss, or raises testosterone are not supported by the published evidence and should be treated skeptically ^[12].

The human record, in plain terms

Three small human pilot studies make up the entire human dataset. A 2025 first-in-human safety pilot gave intravenous BPC-157 (10 mg, then 20 mg by infusion) to two healthy adults and reported it was well tolerated, with no observed adverse events and no measurable changes in cardiac, hepatic, renal, thyroid or glucose biomarkers ^[9]. A 2024 pilot delivered a single intravesical dose during cystoscopy to 12 interstitial-cystitis patients and reported symptom resolution in most (10 of 12 complete) with no reported adverse events ^[11]. A 2025 narrative review weighed the full picture and concluded BPC-157 should be considered investigational: broad preclinical support, extremely limited human data, no rigorous large-scale trials ^[10].

Two people. Twelve people. No controlled trial. That is a signal worth logging precisely — and a base far too small to characterize human efficacy or long-term safety. The human pilot studies of BPC-157 are detailed on the research page, and the full reference list carries every citation with its PMID or DOI.